Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 1.00 |
| ▸ | MMP3 | P08254 | 15/20 | 1.00 |
| ▸ | MMP13 | P45452 | 15/20 | 1.00 |
| ▸ | MMP1 | P03956 | 14/20 | 1.00 |
| ▸ | MMP7 | P09237 | 14/20 | 1.00 |
| ▸ | MMP9 | P14780 | 14/20 | 1.00 |
| ▸ | MMP14 | P50281 | 1/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.78 |
| ▸ | MMP8 | P22894 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7404078 | 1.00 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL4424095 | 1.00 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL8283336 | 0.95 | MMP2 (0.91) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL27611876 | 0.95 | MMP2 (0.91) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL4653257 | 0.88 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL32691806 | 0.88 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL1750956 | 0.88 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL7082523 | 0.87 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL7864111 | 0.87 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL7409278 | 0.87 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| US-20240269138-A1 | MMP13 AS A THERAPEUTIC TARGET FOR ALLERGIC INFLAMMATORY DISEASES | MASSACHUSETTS GEN HOSPITAL (US) | 2024-08-15 | — | — | US | claimed |
| CN-109310775-B | Binary self-assembling gels for controlled delivery of encapsulated agents into cartilage | 布里格姆及妇女医院股份有限公司 | 2022-11-18 | — | — | CN | claimed |
| US-20220331389-A1 | SKIN COMPOSITION | EADERM CO., LTD. (JP) | 2022-10-20 | — | — | US | claimed |
| US-11298372-B2 | Composition for ameliorating loss of hair and graying of hair, and use thereof | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2022-04-12 | — | — | US | claimed |
| EP-3978022-A1 | BINARY SELF ASSEMBLED GELS FOR CONTROLLED DELIVERY OF ENCAPSULATED AGENTS TO CARTILAGE | The Brigham and Women's Hospital, Inc. (US) | 2022-04-06 | — | — | EP | claimed |
| EP-3978020-A1 | SKIN COMPOSITION | National University Corporation Tokyo Medical and Dental University (JP) | 2022-04-06 | — | — | EP | claimed |
| EP-0901466-B1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | claimed |
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0901466-A1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-03-17 | — | — | EP | claimed |
| US-5756545-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | claimed |
| WO-1997044315-A1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-11-27 | — | — | WO | claimed |
| US-20260137788-A1 | INFLAMMATION STIMULI RESPONSIVE PEPTIDE BRUSH POLYMERS | NORTHWESTERN UNIVERSITY (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5756545-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137788-A1 | INFLAMMATION STIMULI RESPONSIVE PEPTIDE BRUSH POLYMERS | FPR1, FPR2, NPY1R | MMP2 1193/4885MMP3 785/4885MMP13 944/4885 |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | SSB, METTL16, TLR9 | MMP2 1500/4885MMP3 220/4885MMP13 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.